OSUR$3.21
Chart
Performance
Key Stats
AI OSUR Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldOraSure Technologies exhibits a mixed investment profile. While its core business in diagnostic products offers a stable revenue base and potential for growth in specific areas, its financial performance has been inconsistent, with recent periods showing significant losses. The company's technological niche and market position are positive, but current valuation and profitability concerns warrant a cautious approach.
Thematic
OraSure Technologies operates within the diagnostics and medical testing sector, which benefits from several ongoing thematic trends including increased healthcare spending, a focus on early disease detection, and the growing demand for point-of-care and at-home testing solutions. The company's portfolio, including its COVID-19 tests and genetic collection devices, aligns with these themes.
Fundamental
OraSure Technologies presents a mixed financial picture. While the company has a strong balance sheet with substantial cash reserves, recent earnings have been negative, and revenue has been volatile. Profitability metrics are concerning, with a negative net income and a low gross profit margin in the most recent periods. The absence of a dividend yield is noted.
Technical
OraSure Technologies' stock exhibits mixed technical signals. The stock is trading above its 50-day and 200-day moving averages, suggesting a generally bullish trend. However, indicators like the RSI are in neutral territory, and the recent performance shows a significant decline (-22.58% over 1 year), indicating potential headwinds or investor caution.
| Factor | Score |
|---|---|
| Healthcare Diagnostics Demand | 85 |
| Point-of-Care & At-Home Testing | 90 |
| Genetic Testing & Personalized Medicine | 70 |
| Pandemic Preparedness & Response | 60 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 20 |
| Growth | 15 |
| Balance Sheet Health | 95 |
| Cash Flow | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 60 |
| Volume Confirmation | 65 |
| Performance | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Short-Term Momentum
The stock price is up 1.20% in pre-market trading, suggesting positive sentiment. Performance over the last month shows an 11.63% increase, indicating recent positive price action.
Supportive Short-Term Moving Averages
Multiple short-term Exponential Moving Averages (10, 20, 30) are showing 'Buy' signals, indicating potential upward momentum in the very short term across various timeframes (1m, 5m, 15m, 30m).
Bearish Points (8)
Negative Recent Performance Trends
The stock has experienced negative performance over the last 6 months (-18.25%) and 1 year (-22.58%), indicating a downward trend that may persist.
Negative Earnings Per Share (EPS)
The trailing EPS is negative (-$0.42), and the company has reported losses in recent quarters (e.g., -$0.21 in 2025Q2, -$0.14 in 2025Q1), signaling profitability challenges.
Calendar
August 2025
6
Next Earnings Date
H: $-0.14
A: $-0.15
L: $-0.16
H: 30.55M
A: 30.36M
L: 30.00M
Profile
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Seasonals
Price Target
6.00 USD
The 39 analysts offering 1 year price forecasts for OSUR have a max estimate of 6.00 and a min estimate of 6.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct acquirer of Ortho-Clinical Diagnostics, inheriting its in-vitro diagnostics portfolio, including clinical chemistry and immunodiagnostics.
Weight: 95
A diversified global healthcare giant with a leading diagnostics division offering broad solutions in immunodiagnostics, clinical chemistry, molecular diagnostics, and point-of-care testing, directly competing with and complementing former Ortho-Clinical areas.
Weight: 93
Global leader in in-vitro diagnostics, with extensive offerings in clinical chemistry, immunodiagnostics, molecular diagnostics, and tissue diagnostics, representing a major competitor to the legacy Ortho-Clinical business.
Weight: 90
Diversified science and technology conglomerate whose diagnostics segment (including Beckman Coulter and Leica Biosystems) is a major player in clinical chemistry, immunoassay, and molecular diagnostics.